vs
嘉德诺（BTSG）与CSX Corporation（CSX）财务数据对比。点击上方公司名可切换其他公司
嘉德诺的季度营收约是CSX Corporation的1.0倍（$3.6B vs $3.5B），CSX Corporation净利率更高（23.2% vs 2.2%，领先21.0%），嘉德诺同比增速更快（16.3% vs 1.7%），CSX Corporation自由现金流更多（$793.0M vs $193.9M），过去两年嘉德诺的营收复合增速更高（17.4% vs -3.0%）
嘉德诺是美国跨国医疗服务企业，位列美国企业营收榜第15位，总部位于俄亥俄州都柏林。公司主营药品与医疗产品分销，服务覆盖超10万个网点，同时生产手套、手术服、流体管理产品等医用外科用品，还运营着规模位居前列的放射性药物网络。
CSX运输是美国一级货运铁路企业，业务覆盖美国东部区域及加拿大安大略省、魁北克省，运营铁路总里程约3.4万公里，隶属于总部位于佛罗里达州杰克逊维尔市的财富500强企业CSX Corporation，是其旗下核心子公司。
BTSG vs CSX — 直观对比
营收规模更大
BTSG
是对方的1.0倍
$3.5B
营收增速更快
BTSG
高出14.6%
1.7%
净利率更高
CSX
高出21.0%
2.2%
自由现金流更多
CSX
多$599.1M
$193.9M
两年增速更快
BTSG
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $3.5B |
| 净利润 | $77.1M | $807.0M |
| 毛利率 | 11.6% | — |
| 营业利润率 | 3.0% | 29.9% |
| 净利率 | 2.2% | 23.2% |
| 营收同比 | 16.3% | 1.7% |
| 净利润同比 | 381.8% | 401.2% |
| 每股收益（稀释后） | $0.34 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BTSGCSX
| Q1 26 | — | $3.5B | ||
| Q4 25 | $3.6B | $3.5B | ||
| Q3 25 | $3.3B | $3.6B | ||
| Q2 25 | $3.1B | $3.6B | ||
| Q1 25 | $2.9B | $3.4B | ||
| Q4 24 | $3.1B | $3.5B | ||
| Q3 24 | $2.9B | $3.6B | ||
| Q2 24 | $2.7B | $3.7B |
净利润BTSGCSX
| Q1 26 | — | $807.0M | ||
| Q4 25 | $77.1M | $720.0M | ||
| Q3 25 | $55.8M | $694.0M | ||
| Q2 25 | $28.2M | $829.0M | ||
| Q1 25 | $29.5M | $646.0M | ||
| Q4 24 | $16.0M | $720.0M | ||
| Q3 24 | $-8.2M | $894.0M | ||
| Q2 24 | $19.9M | $963.0M |
毛利率BTSGCSX
| Q1 26 | — | — | ||
| Q4 25 | 11.6% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 11.8% | — | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 14.2% | — |
营业利润率BTSGCSX
| Q1 26 | — | 29.9% | ||
| Q4 25 | 3.0% | 31.6% | ||
| Q3 25 | 2.6% | 30.3% | ||
| Q2 25 | 1.5% | 35.9% | ||
| Q1 25 | 1.8% | 30.4% | ||
| Q4 24 | 2.6% | 30.8% | ||
| Q3 24 | 2.0% | 37.4% | ||
| Q2 24 | 2.3% | 39.1% |
净利率BTSGCSX
| Q1 26 | — | 23.2% | ||
| Q4 25 | 2.2% | 20.5% | ||
| Q3 25 | 1.7% | 19.3% | ||
| Q2 25 | 0.9% | 23.2% | ||
| Q1 25 | 1.0% | 18.9% | ||
| Q4 24 | 0.5% | 20.3% | ||
| Q3 24 | -0.3% | 24.7% | ||
| Q2 24 | 0.7% | 26.0% |
每股收益（稀释后）BTSGCSX
| Q1 26 | — | — | ||
| Q4 25 | $0.34 | $0.39 | ||
| Q3 25 | $0.26 | $0.37 | ||
| Q2 25 | $0.13 | $0.44 | ||
| Q1 25 | $0.14 | $0.34 | ||
| Q4 24 | $0.11 | $0.38 | ||
| Q3 24 | $-0.04 | $0.46 | ||
| Q2 24 | $0.10 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $88.4M | $1.1B |
| 总债务越低越好 | $2.5B | $18.9B |
| 股东权益账面价值 | $1.9B | $13.6B |
| 总资产 | $6.4B | $44.2B |
| 负债/权益比越低杠杆越低 | 1.34× | 1.39× |
8季度趋势，按日历期对齐
现金及短期投资BTSGCSX
| Q1 26 | — | $1.1B | ||
| Q4 25 | $88.4M | $5.0M | ||
| Q3 25 | $140.3M | $6.0M | ||
| Q2 25 | $70.1M | $6.0M | ||
| Q1 25 | $52.3M | $8.0M | ||
| Q4 24 | $61.3M | $72.0M | ||
| Q3 24 | $36.0M | $12.0M | ||
| Q2 24 | $25.0M | $4.0M |
总债务BTSGCSX
| Q1 26 | — | $18.9B | ||
| Q4 25 | $2.5B | $18.2B | ||
| Q3 25 | $2.5B | $18.6B | ||
| Q2 25 | $2.5B | $18.6B | ||
| Q1 25 | $2.5B | $18.5B | ||
| Q4 24 | $2.6B | $17.9B | ||
| Q3 24 | $2.7B | $18.5B | ||
| Q2 24 | $2.6B | $18.0B |
股东权益BTSGCSX
| Q1 26 | — | $13.6B | ||
| Q4 25 | $1.9B | $13.2B | ||
| Q3 25 | $1.8B | $12.8B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.2B | ||
| Q4 24 | $1.6B | $12.5B | ||
| Q3 24 | $1.6B | $12.9B | ||
| Q2 24 | $1.6B | $12.6B |
总资产BTSGCSX
| Q1 26 | — | $44.2B | ||
| Q4 25 | $6.4B | $43.7B | ||
| Q3 25 | $6.0B | $43.3B | ||
| Q2 25 | $5.9B | $42.9B | ||
| Q1 25 | $5.8B | $43.2B | ||
| Q4 24 | $5.9B | $42.8B | ||
| Q3 24 | $5.8B | $43.1B | ||
| Q2 24 | $5.6B | $42.4B |
负债/权益比BTSGCSX
| Q1 26 | — | 1.39× | ||
| Q4 25 | 1.34× | 1.38× | ||
| Q3 25 | 1.38× | 1.45× | ||
| Q2 25 | 1.45× | 1.50× | ||
| Q1 25 | 1.50× | 1.52× | ||
| Q4 24 | 1.58× | 1.43× | ||
| Q3 24 | 1.65× | 1.43× | ||
| Q2 24 | 1.63× | 1.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $231.6M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $193.9M | $793.0M |
| 自由现金流率自由现金流/营收 | 5.5% | 22.8% |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 3.00× | 1.58× |
| 过去12个月自由现金流最近4个季度 | $394.7M | $2.0B |
8季度趋势，按日历期对齐
经营现金流BTSGCSX
| Q1 26 | — | $1.3B | ||
| Q4 25 | $231.6M | $1.4B | ||
| Q3 25 | $107.9M | $1.3B | ||
| Q2 25 | $49.1M | $635.0M | ||
| Q1 25 | $101.6M | $1.3B | ||
| Q4 24 | $90.6M | $1.4B | ||
| Q3 24 | $27.2M | $1.7B | ||
| Q2 24 | $-15.2M | $1.1B |
自由现金流BTSGCSX
| Q1 26 | — | $793.0M | ||
| Q4 25 | $193.9M | $709.0M | ||
| Q3 25 | $92.2M | $607.0M | ||
| Q2 25 | $24.7M | $-141.0M | ||
| Q1 25 | $84.0M | $536.0M | ||
| Q4 24 | $75.3M | $550.0M | ||
| Q3 24 | $7.2M | $1.1B | ||
| Q2 24 | $-39.0M | $547.0M |
自由现金流率BTSGCSX
| Q1 26 | — | 22.8% | ||
| Q4 25 | 5.5% | 20.2% | ||
| Q3 25 | 2.8% | 16.9% | ||
| Q2 25 | 0.8% | -3.9% | ||
| Q1 25 | 2.9% | 15.7% | ||
| Q4 24 | 2.5% | 15.5% | ||
| Q3 24 | 0.2% | 29.3% | ||
| Q2 24 | -1.4% | 14.8% |
资本支出强度BTSGCSX
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 19.3% | ||
| Q3 25 | 0.5% | 20.4% | ||
| Q2 25 | 0.8% | 21.7% | ||
| Q1 25 | 0.6% | 21.0% | ||
| Q4 24 | 0.5% | 23.7% | ||
| Q3 24 | 0.7% | 17.3% | ||
| Q2 24 | 0.9% | 14.6% |
现金转化率BTSGCSX
| Q1 26 | — | 1.58× | ||
| Q4 25 | 3.00× | 1.93× | ||
| Q3 25 | 1.93× | 1.93× | ||
| Q2 25 | 1.74× | 0.77× | ||
| Q1 25 | 3.44× | 1.94× | ||
| Q4 24 | 5.66× | 1.93× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | -0.76× | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BTSG
| Medicare D | $1.1B | 32% |
| Commercial Insurance | $879.8M | 25% |
| Medicare C | $641.2M | 18% |
| Provider Services | $394.2M | 11% |
| Medicaid | $301.4M | 8% |
| Medicare A | $150.5M | 4% |
| Private And Other | $44.0M | 1% |
| Medicare B | $19.5M | 1% |
| Pharmacy Solutions And Provider Services Segments | $19.0M | 1% |
CSX
暂无分部数据
